Home Cellular science Applied Molecular Transport to Present at Upcoming November Investor Conferences

Applied Molecular Transport to Present at Upcoming November Investor Conferences


SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in the following investor conferences :

Event: Guggenheim 4e Annual day of immunology and neurology
Format: Corporate Presentation
Date and hour : Monday, November 14, 2022 at 9:35 a.m. ET
Location: New York, New York
Presenter: Tahir Mahmood, Ph.D., CEO and Co-Founder

Event: Jefferies London Healthcare Conference
Format: Fireside Chat
Date and hour : Wednesday, November 16, 2022, at 1:30 p.m. GMT
Location: London, UK
Presenters: Shawn Cross, President and Chief Operating Officer, and Bittoo Kanwar, MD, Chief Medical Officer

The live webcasts will be accessible through the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. Archived replays will be available for 30 days after the events.

About Applied Molecular Transport Inc.

AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, leveraging its technology platform to engineer biologic product candidates into patient-tailored oral dosage forms. AMT’s product candidates are designed to precisely target relevant disease pathophysiology. AMT’s proprietary technology platform is integrated into its product candidates, leveraging existing natural cellular trafficking pathways to drive the active transport of various therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier.

AMT’s corporate headquarters, in-house GMP manufacturing and laboratory facilities are located in South San Francisco, CA. For more information on the AMT, please visit www.appliedmt.com.

Contact with Investor Relations:
Andrew Chang
Head, Investor Relations and Corporate Communications
[email protected]

Media contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]